Le Lézard
Classified in: Health, Covid-19 virus
Subjects: PSF, AVO

Christ the Redeemer gets a mask against COVID-19


Projection on one of the world's most iconic monuments is part of a campaign to encourage the use of masks as a way of preventing the new coronavirus

SÃO PAULO, May 4, 2020 /PRNewswire/ -- Used by many people on the streets of Brazil and the world today, a mask also covered the nose and mouth of the largest Brazilian icon: Christ the Redeemer. Part of the Todos pela Saúde (All for Health) initiative, an alliance of health experts created with the objective of combating the new coronavirus and its effects on Brazilian society, the action highlights the importance of protecting everyone when leaving home and amplifies the message #MaskSaves. The projection took place between 7 and 10 pm this Sunday (May, 3rd). A video with the projection can be found here: https://we.tl/t-Aw5RL82qC5

Christ the Redeemer gets mask to encourage the world protect against Covid-19

"The Redemptive Christ presents itself once again as the ultimate symbol for the formation of a collective conscience for the preservation of life", said Father Omar, rector of the Christ the Redeemer Sanctuary.

The use of protective masks has been one of the main recommendations of authorities to prevent the spread of the new coronavirus. The measure is in line with recent medical studies that prove the high transmission capacity of asymptomatic people, making it essential to use protection even for those who do not have fever, cough, headache or sore throat. Thus, the initiative is important to reduce the levels of contamination in social contact.

Todos pela Saúde (All for Health)
The campaign to encourage the use of masks is part of the Todos pela Saúde initiative, created with the objective of combating the new coronavirus and its effects on Brazilian society. Comprising four axes - informing, protecting, caring and resuming - the initiative ranges from guidance and enhancement of existing initiatives to the purchase of health equipment, training of health professionals and purchase and distribution of inputs.

Itaú, the largest bank in Latin America, directed US$ 200 million to finance the creation and activities of Todos pela Saúde. The funds are being managed by a group of specialists led by doctor Paulo Chapchap, doctor in surgical clinic by the University of São Paulo and general director at Hospital Sírio Libanês, one of the largest in Brazil. This team is already defining actions to be financed, so that strategic decisions are supported by technical and scientific premises.

Photo - https://mma.prnewswire.com/media/1163363/Christ_the_Redeemer_gets_mask_light.jpg  


These press releases may also interest you

at 11:30
Nature's Miracle Holdings Inc. ("Nature's Miracle"), a leader in vertical farming technology and infrastructure, today announced the successful manufacturing and shipment of its first two customized container farms in its proprietary "MiracleTainer"...

at 11:05
Parsec Automation Corp. has been recognized by the American Business Awards® ("Stevie Awards®") for its significant contributions to progress in the manufacturing industry and commitment to going above and beyond for its customers. The company was...

at 11:00
IPv4.Global, the world's largest, most-trusted and transparent IPv4 marketplace, today announced it was named the winner of a Silver Stevie® Award in the Fastest Growing Company of the Year - Up to 100 Employees category in The 22nd Annual American...

at 10:52
Today, The Bronx Social Care Network (BSCN), a coalition of Bronx-based federally qualified community health centers (FQHCs) partnering with more than 50 Bronx-based community-based organizations (CBOs), led by Urban Health Plan, one of the largest...

at 10:15
More automation and artificial intelligence integration, improved capabilities for virtual and hybrid events, and an emphasis on data-driven insights and personalisation are what the Event Management Software Market will see in the future....

at 10:12
Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that results from the ibezapolstat Phase 2 clinical...



News published on and distributed by: